普拉克索联合艾司西酞普兰治疗帕金森病伴轻度认知障碍和抑郁患者的价值研究
|
摘要
目的:探析应用普拉克索与艾司西酞普兰联合治疗帕金森病伴轻度认知障碍和抑郁患者的应用效果及价值。方法:在2016年3月至2018年6月期间选取72例于我院进行诊治的帕金森病伴轻度认知障碍和抑郁患者,根据患者就诊时间的先后平均地将其分为单一组和联合组,各36例。单一组单独采用普拉克索进行治疗,联合组采用普拉克索与艾司西酞普兰进行联合治疗,比较两组用药方案的疗效。结果:两组患者治疗后UPDRS各维度的评分以及HAMD评分均明显低于治疗前,MoCA评分均明显高于治疗前;经组间比较发现,联合组患者治疗后的UPDRS评分、HAMD评分相对低于单一组,MoCA评分相对高于单一组,且P<0.05,差异具统计学意义。联合组患者与单一组患者的不良反应的总发生率分别为27.78%与22.22%,其组间差异较小,无统计学意义(P>0.05)。结论:普拉克索联合艾司西酞普兰治疗疗帕金森病伴轻度认知障碍和抑郁患者的疗效较好,可促进患者病情的改善,减轻认知障碍和抑郁程度,且不良反应发生率与单独用药相比无显著差异,安全性较高,值得推广。
Objective: To explore the effect and value of combined use of Praxol and estalopram in the treatment of Parkinson's disease with mild cognitive impairment and depression. Methods: From March 2016 to June 2018, 72 cases of Parkinson's disease with mild cognitive impairment and depression were selected and divided into a single group(36 cases) and a combined group(36 cases). The single group was treated with Praxol alone and the combined group with praxol and Escitalopram. Results: The scores of UPDRS and HAMD after treatment in both groups were significantly lower than those before treatment and, Mo CA scores were significantly higher than those before treatment. It was found that the UPDRS score of the combined group was lower than that of the single group(P<0.05), and the HAMD score of the combined group was lower than that of the single group(P<0.05). The total incidence of adverse reactions was 27.78% in the combined group and 22.22% in the single group. The difference between the two groups was not statistically significant(P>0.05). Conclusion: Praxol combined with Escitalopram in the treatment of Parkinson's disease with mild cognitive impairment can improve the patients' condition, reduce cognitive impairment and depression degree, and the incidence of adverse reactions has no significant difference compared with the treatment alone. Therefore, the safety is higher, it is worth popularizing.
Objective: To explore the effect and value of combined use of Praxol and estalopram in the treatment of Parkinson's disease with mild cognitive impairment and depression. Methods: From March 2016 to June 2018, 72 cases of Parkinson's disease with mild cognitive impairment and depression were selected and divided into a single group(36 cases) and a combined group(36 cases). The single group was treated with Praxol alone and the combined group with praxol and Escitalopram. Results: The scores of UPDRS and HAMD after treatment in both groups were significantly lower than those before treatment and, Mo CA scores were significantly higher than those before treatment. It was found that the UPDRS score of the combined group was lower than that of the single group(P<0.05), and the HAMD score of the combined group was lower than that of the single group(P<0.05). The total incidence of adverse reactions was 27.78% in the combined group and 22.22% in the single group. The difference between the two groups was not statistically significant(P>0.05). Conclusion: Praxol combined with Escitalopram in the treatment of Parkinson's disease with mild cognitive impairment can improve the patients' condition, reduce cognitive impairment and depression degree, and the incidence of adverse reactions has no significant difference compared with the treatment alone. Therefore, the safety is higher, it is worth popularizing.
引文
[1]赖智勇,黄琳明,韩慧,等.艾司西酞普兰联合氟西汀对脑梗死患者认知功能障碍伴发抑郁的临床疗效分析[J].国际精神病学杂志, 2017, 44(02):69-71.
[2]张帆,李运祥,成亚纯,等.吡贝地尔与艾司西酞普兰联合用药对帕金森伴抑郁状态患者抑郁评分及神经症状康复的影响[J].国际精神病学杂志, 2017, 44(3):477-479.
[3]姜童子,陈鑫.帕金森病患者治疗中预防性给予小剂量艾司西酞普兰对PDQ-39、UPDR及HAMD评分的影响分析[J].脑与神经疾病杂志, 2018, 26(3):180-184.
[4]屠海玲,陈国强,王丽平,等.吡贝地尔联合艾司西酞普兰对帕金森患者运动功能及认知功能的影响[J].河北医药, 2017, 39(2):201-203.
[5]宋晓玲,孟文,毛碧容.吡贝地尔联合艾司西酞普兰对帕金森病病人运动功能及认知功能的影响[J].中西医结合心脑血管病杂志, 2018, 16(6):801-805.
[6]古力巴克然木·阿布拉,马瑞,胡曼娜,等.西酞普兰联合心理干预对抑郁症患者症状及认知功能的疗效[J].国际精神病学杂志, 2017, 44(4):625-627.
[7]侯宇,娄伟,薛天宇,等.多巴丝肼与普拉克索对帕金森病不同认知障碍程度患者血同型半胱氨酸和胱抑素C水平的影响[J].医学与哲学, 2018, 39(1):36-39.
[8]焦琳娜,章小兵,曹欣.盐酸普拉克索对帕金森病合并抑郁患者非运动症状及睡眠质量的影响[J].中国医药导报, 2016, 13(18):153-156.
[9]马义鹏,胡为民,梁蔚骏,等.普拉克索缓释片治疗原发性帕金森病非运动症状的临床观察[J].中国药物与临床, 2017, 17(8):1191-1194.
[10]郎素芝.司来吉兰联合普拉克索治疗帕金森病伴抑郁的疗效观察[J].现代药物与临床, 2015, 30(8):983-986.
[11]王琪,孙新艳,赵理荣,等.普拉克索联合艾司西酞普兰治疗帕金森病伴轻度认知障碍和抑郁患者的效果[J].国际精神病学杂志, 2018, 45(2):311-313.
[12]白剑文,曾涛,高瑞英,等.普拉克索联合艾司西酞普兰治疗帕金森病轻度认知障碍伴发抑郁疗效的临床研究[J].国际精神病学杂志, 2016, 43(5):813-816.
[2]张帆,李运祥,成亚纯,等.吡贝地尔与艾司西酞普兰联合用药对帕金森伴抑郁状态患者抑郁评分及神经症状康复的影响[J].国际精神病学杂志, 2017, 44(3):477-479.
[3]姜童子,陈鑫.帕金森病患者治疗中预防性给予小剂量艾司西酞普兰对PDQ-39、UPDR及HAMD评分的影响分析[J].脑与神经疾病杂志, 2018, 26(3):180-184.
[4]屠海玲,陈国强,王丽平,等.吡贝地尔联合艾司西酞普兰对帕金森患者运动功能及认知功能的影响[J].河北医药, 2017, 39(2):201-203.
[5]宋晓玲,孟文,毛碧容.吡贝地尔联合艾司西酞普兰对帕金森病病人运动功能及认知功能的影响[J].中西医结合心脑血管病杂志, 2018, 16(6):801-805.
[6]古力巴克然木·阿布拉,马瑞,胡曼娜,等.西酞普兰联合心理干预对抑郁症患者症状及认知功能的疗效[J].国际精神病学杂志, 2017, 44(4):625-627.
[7]侯宇,娄伟,薛天宇,等.多巴丝肼与普拉克索对帕金森病不同认知障碍程度患者血同型半胱氨酸和胱抑素C水平的影响[J].医学与哲学, 2018, 39(1):36-39.
[8]焦琳娜,章小兵,曹欣.盐酸普拉克索对帕金森病合并抑郁患者非运动症状及睡眠质量的影响[J].中国医药导报, 2016, 13(18):153-156.
[9]马义鹏,胡为民,梁蔚骏,等.普拉克索缓释片治疗原发性帕金森病非运动症状的临床观察[J].中国药物与临床, 2017, 17(8):1191-1194.
[10]郎素芝.司来吉兰联合普拉克索治疗帕金森病伴抑郁的疗效观察[J].现代药物与临床, 2015, 30(8):983-986.
[11]王琪,孙新艳,赵理荣,等.普拉克索联合艾司西酞普兰治疗帕金森病伴轻度认知障碍和抑郁患者的效果[J].国际精神病学杂志, 2018, 45(2):311-313.
[12]白剑文,曾涛,高瑞英,等.普拉克索联合艾司西酞普兰治疗帕金森病轻度认知障碍伴发抑郁疗效的临床研究[J].国际精神病学杂志, 2016, 43(5):813-816.